• December 26, 2019  

    Triplet Regimen Offers Improved Outcomes in BRAF-Mutant Colorectal Cancer Bookmark

    George Lundberg, MD

    Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

    In a phase III clinical trial, a triple-drug therapy nearly triples overall survival for patients with colorectal cancer.

    Go to full article published by Cancer Network.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 13, 2019  

    Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients with Locally Advanced or Metastatic Urothelial Carcinoma After Platinum-Based Therapy (RANGE): Overall Survival and Updated Results of a Randomised, Double-Blind, Phase 3 Trial Bookmark

    George Lundberg, MD

    Research paper from The Lancet curated by Editor in Chief George Lundberg, MD, who notes: 

    A drug called Cyramza improves progession-free survival (PFS) but not overall survival (OS) of patients with advanced bladder cancer in a phase lll clinical trial.

    Go to full paper published in The Lancet.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 13, 2019  

    PARP Inhibitors Center Stage for Ovarian Cancer Bookmark

    George Lundberg, MD

    Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

    Drugs known as PARP inhibitors can improve progression-free survival (PFS) in many patients with advanced ovarian cancers.

    Go to full article published by Medscape.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019  

    Long-term Survival in Esophageal Cancer After Minimally Invasive Compared to Open Esophagectomy: A Systematic Review and Meta-analysis Bookmark

    George Lundberg, MD

    Research paper from Annals of Surgery curated by Editor in Chief George Lundberg, MD, who notes: 

    This meta-analysis found that minimally invasive surgery tops open esophagectomy for esophageal cancer.

    Go to full paper published in Annals of Surgery.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019  

    Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial Bookmark

    George Lundberg, MD

    Research paper from the Journal of Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    Niraparib substantially improves TWIST (time without symptoms or toxicity) over no treatment in recurrent epithelial ovarian cancers, even moreso if positive for gBRCAmu.

    Go to full paper published in the Journal of Clinical Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019  

    ESMO Asia 2019: Combination of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma Bookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    In a clinical trial, a new combination therapy conferred better response rates, progression-free survival, and overall survival than standard sorafinib for unresectable hepatocellular carcinoma.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019  

    Does the Artery-first Approach Improve the Rate of R0 Resection in Pancreatoduodenectomy?: A Multicenter, Randomized, Controlled Trial Bookmark

    George Lundberg, MD

    Research paper from Annals of Surgery curated by Editor in Chief George Lundberg, MD, who notes: 

    This clinical trial found no difference in tumor-free margins from standard versus artery-first surgical techniques for the resection of pancreatic head adenocarcinoma via pancreatoduodenectomy.

    Go to full paper published in Annals of Surgery.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019  

    Nivolumab Versus Chemotherapy in Patients with Advanced Oesophageal Squamous Cell Carcinoma Refractory or Intolerant to Previous Chemotherapy (Attraction-3): A Multicentre, Randomised, Open-Label, Phase 3 Trial Bookmark

    George Lundberg, MD

    Research paper from The Lancet curated by Editor in Chief George Lundberg, MD, who notes: 

    In this clinical trial, nivolumab was somewhat superior to chemotherapy for advanced esophageal carcinoma.

    Go to full paper published in The Lancet.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • November 12, 2019  

    ADMIRAL: Gilteritinib vs Chemotherapy in Relapsed or Refractory FLT3-Mutated AML Bookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    A clinical trial showed substantial benefits of progression-free survival and overall survival for patients with a particular form of acute myeloid leukemia when treated by gilteritinib versus chemotherapy. However, the disease was still fatal.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • November 12, 2019  

    Less Invasive Surgery Wins in Esophageal Cancer Bookmark

    George Lundberg, MD

    Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

    Minimally invasive surgery for esophageal cancer produces similar outcomes with fewer complications than open surgery. A reduction in pulmonary atelectasis may underlie these findings.

    Go to full article published by MedPage Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.